Functional and Cutaneous Treatment Outcomes With Intravenous Immunoglobulin for Eosinophilic Fasciitis: A Retrospective Study

April 2024 | Volume 23 | Issue 4 | e107 | Copyright © April 2024


Published online March 7, 2024

Bianca Obiakor BAa, Winnie Fan BSa, Rebecca Jacobson BMb, Jocelyn Gandelman MDc, Anna Haemel MDd

aUniversity of California, San Francisco, School of Medicine, San Francisco, CA 
bUniversity of California, Irvine, School of Medicine, Irvine, CA 
cSchweiger Dermatology Group, New York, NY 
dDepartment of Dermatology, University of California, San Francisco, San Francisco, CA
 

findings from the largest cohort of adults with EF treated with IVIG to date, offering additional support for the use of IVIG as an adjunctive treatment to traditional systemic therapies, particularly in recalcitrant cases. 
 

DISCLOSURES

Author A.H. is a consultant to CSL Behring and Guidepoint LLC. Other authors have no conflicts to report.

IRB approval status: Reviewed and approved by UCSF Parnassus Committee; #348854.

Financial disclosures: This work was supported by the University of California, San Francisco School of Medicine Summer Explore Grant.
 

REFERENCES

  1. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70-86. 
  2. Wright NA, Mazori DR, Patel M, et al. Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol. 2016;152(1):97-99. 
  3. Lebeaux D, Francès C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology. 2012;51(3):557-561. 
  4. Erez D, Shoenfeld Y, Natour A, et al. Clinical experience with biologic treatment in resistant eosinophilic fasciitis: Case reports and literature review. Medicine (Baltimore). 2021;100(13):e25359. 
  5. Tkachenko E, Steuer AB, Lo K, et al. Intravenous immunoglobulin for refractory eosinophilic fasciitis: a retrospective analysis from 3 tertiary care centers. J Am Acad Dermatol. 2019;S0190-9622(19):33297-33299. 
  6. Pimenta S, Bernardes M, Bernardo A, et al. Intravenous immune globulins to treat eosinophilic fasciitis: a case report. Joint Bone Spine. 2009;76(5):572-574. 

AUTHOR CORRESPONDENCE

Anna Haemel MD anna.haemel@ucsf.edu
Close Menu